483 related articles for article (PubMed ID: 28814431)
1. Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis.
Jonsson MK; Sundlisæter NP; Nordal HH; Hammer HB; Aga AB; Olsen IC; Brokstad KA; van der Heijde D; Kvien TK; Fevang BS; Lillegraven S; Haavardsholm EA
Ann Rheum Dis; 2017 Dec; 76(12):2031-2037. PubMed ID: 28814431
[TBL] [Abstract][Full Text] [Related]
2. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab.
Nordal HH; Brun JG; Hordvik M; Eidsheim M; Jonsson R; Halse AK
Scand J Rheumatol; 2016 Jul; 45(4):274-81. PubMed ID: 26767827
[TBL] [Abstract][Full Text] [Related]
3. Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis.
Hurnakova J; Zavada J; Hanova P; Hulejova H; Klein M; Mann H; Sleglova O; Olejarova M; Forejtova S; Ruzickova O; Komarc M; Vencovsky J; Pavelka K; Senolt L
Arthritis Res Ther; 2015 Sep; 17(1):252. PubMed ID: 26373925
[TBL] [Abstract][Full Text] [Related]
4. Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis.
Hammer HB; Ødegård S; Syversen SW; Landewé R; van der Heijde D; Uhlig T; Mowinckel P; Kvien TK
Ann Rheum Dis; 2010 Jan; 69(1):150-4. PubMed ID: 19095696
[TBL] [Abstract][Full Text] [Related]
5. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
[TBL] [Abstract][Full Text] [Related]
6. Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis.
Nordal HH; Brokstad KA; Solheim M; Halse AK; Kvien TK; Hammer HB
Arthritis Res Ther; 2017 Jan; 19(1):3. PubMed ID: 28081709
[TBL] [Abstract][Full Text] [Related]
7. The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy.
Jonsson MK; Hensvold AH; Hansson M; Aga AB; Sexton J; Mathsson-Alm L; Cornillet M; Serre G; Lillegraven S; Fevang BS; Catrina AI; Haavardsholm EA
Arthritis Res Ther; 2018 Jul; 20(1):146. PubMed ID: 30001740
[TBL] [Abstract][Full Text] [Related]
8. Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors.
Inciarte-Mundo J; Victoria Hernández M; Ruiz-Esquide V; Raquel Cabrera-Villalba S; Ramirez J; Cuervo A; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Care Res (Hoboken); 2016 Jul; 68(7):899-906. PubMed ID: 26841119
[TBL] [Abstract][Full Text] [Related]
9. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis.
Hammer HB; Odegard S; Fagerhol MK; Landewé R; van der Heijde D; Uhlig T; Mowinckel P; Kvien TK
Ann Rheum Dis; 2007 Aug; 66(8):1093-7. PubMed ID: 17234650
[TBL] [Abstract][Full Text] [Related]
10. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants.
Inciarte-Mundo J; Ruiz-Esquide V; Hernández MV; Cañete JD; Cabrera-Villalba SR; Ramirez J; Yagüe J; Sanmarti R
Rheumatology (Oxford); 2015 Dec; 54(12):2239-43. PubMed ID: 26242859
[TBL] [Abstract][Full Text] [Related]
11. Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission.
Hurnakova J; Hulejova H; Zavada J; Komarc M; Hanova P; Klein M; Mann H; Sleglova O; Olejarova M; Forejtova S; Ruzickova O; Vencovsky J; Pavelka K; Senolt L
PLoS One; 2016; 11(11):e0165498. PubMed ID: 27832086
[TBL] [Abstract][Full Text] [Related]
12. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study.
Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Res Ther; 2018 Dec; 20(1):275. PubMed ID: 30545393
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers in Remission According to Different Criteria in Patients with Rheumatoid Arthritis.
Yilmaz-Oner S; Ozen G; Can M; Atagunduz P; Direskeneli H; Inanc N
J Rheumatol; 2015 Nov; 42(11):2066-70. PubMed ID: 26472417
[TBL] [Abstract][Full Text] [Related]
14. Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: associations to future good radiographic and physical outcomes.
Paulshus Sundlisæter N; Aga AB; Olsen IC; Hammer HB; Uhlig T; van der Heijde D; Kvien TK; Lillegraven S; Haavardsholm EA;
Ann Rheum Dis; 2018 Oct; 77(10):1421-1425. PubMed ID: 29934373
[TBL] [Abstract][Full Text] [Related]
15. Clinical and sonographic biomarkers of structural damage progression in RA patients in clinical remission: A prospective study with 12 months follow-up.
Ramírez J; Narváez JA; Ruiz-Esquide V; Hernández-Gañán J; Cuervo A; Inciarte-Mundo J; Hernández MV; Sampayo-Cordero M; Pablos JL; Sanmartí R; Cañete JD
Semin Arthritis Rheum; 2017 Dec; 47(3):303-309. PubMed ID: 28549731
[TBL] [Abstract][Full Text] [Related]
16. Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial.
Dale J; Stirling A; Zhang R; Purves D; Foley J; Sambrook M; Conaghan PG; van der Heijde D; McConnachie A; McInnes IB; Porter D
Ann Rheum Dis; 2016 Jun; 75(6):1043-50. PubMed ID: 27026689
[TBL] [Abstract][Full Text] [Related]
17. Calprotectin in rheumatoid arthritis : association with disease activity in a cross-sectional and a longitudinal cohort.
García-Arias M; Pascual-Salcedo D; Ramiro S; Ueberschlag ME; Jermann TM; Cara C; Martín-Mola E; Balsa A
Mol Diagn Ther; 2013 Feb; 17(1):49-56. PubMed ID: 23329363
[TBL] [Abstract][Full Text] [Related]
18. Calprotectin levels in patients with rheumatoid arthritis to assess and association with exercise treatment.
Acar A; Guzel S; Sarifakioglu B; Guzel EC; Guzelant AY; Karadag C; Kiziler L
Clin Rheumatol; 2016 Nov; 35(11):2685-2692. PubMed ID: 27094943
[TBL] [Abstract][Full Text] [Related]
19. Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein.
Hurnakova J; Hulejova H; Zavada J; Komarc M; Cerezo LA; Mann H; Vencovsky J; Pavelka K; Senolt L
Clin Rheumatol; 2018 Aug; 37(8):2055-2062. PubMed ID: 29656372
[TBL] [Abstract][Full Text] [Related]
20. Calprotectin (a major leucocyte protein) is associated with the levels of anti-CCP and rheumatoid factor in a longitudinal study of patients with very early rheumatoid arthritis.
Hammer HB; Haavardsholm EA; Kvien TK
Scand J Rheumatol; 2008; 37(3):179-82. PubMed ID: 18465451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]